Ser241
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser241  -  PDK1 (human)

Site Information
skQARANsFVGtAQy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447693
Available spectra:  11 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 308 , 314 ) , [32P] bio-synthetic labeling ( 314 , 322 ) , electrophoretic mobility shift ( 314 ) , flow cytometry ( 8 ) , immunoprecipitation ( 3 , 8 , 220 , 297 ) , mass spectrometry ( 4 , 5 , 6 , 10 , 11 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 124 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 308 , 318 ) , mutation of modification site ( 314 , 319 , 321 , 322 ) , peptide sequencing ( 322 ) , phospho-antibody ( 1 , 2 , 3 , 8 , 9 , 12 , 16 , 39 , 68 , 92 , 105 , 106 , 123 , 125 , 220 , 242 , 266 , 297 , 298 , 306 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 319 , 320 ) , phosphoamino acid analysis ( 206 ) , phosphopeptide mapping ( 314 , 322 ) , western blotting ( 1 , 2 , 3 , 8 , 9 , 12 , 16 , 39 , 68 , 92 , 105 , 106 , 123 , 125 , 206 , 220 , 242 , 297 , 298 , 306 , 310 , 313 , 314 , 315 , 316 )
Disease tissue studied:
bone cancer ( 233 ) , osteosarcoma ( 233 ) , brain cancer ( 8 ) , glioblastoma multiforme ( 8 ) , glioma ( 8 ) , breast cancer ( 3 , 10 , 18 , 19 , 39 , 42 , 46 , 106 , 220 , 309 , 313 , 314 ) , breast adenocarcinoma ( 39 ) , breast ductal carcinoma ( 18 ) , HER2 positive breast cancer ( 6 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, surrounding tissue ( 6 ) , breast cancer, triple negative ( 6 , 18 , 39 ) , cervical cancer ( 106 , 241 ) , cervical adenocarcinoma ( 241 ) , colorectal cancer ( 106 , 298 , 316 ) , colorectal carcinoma ( 106 , 298 , 316 ) , endometrial cancer ( 125 ) , endometrial adenocarcinoma ( 125 ) , gastric cancer ( 44 , 64 , 65 , 66 , 67 , 94 , 107 , 129 , 138 , 142 , 209 , 210 , 213 , 214 , 215 , 225 , 227 , 229 , 260 , 261 , 263 , 264 ) , gastric carcinoma ( 64 , 65 , 66 , 67 , 94 , 107 , 129 , 138 , 142 , 209 , 210 , 213 , 214 , 215 , 225 , 227 , 229 , 260 , 261 , 263 , 264 ) , gestational cancer ( 123 ) , gestational trophoblastic choriocarcinoma ( 123 ) , leukemia ( 4 , 9 , 63 , 68 , 105 , 145 , 211 , 212 , 232 , 303 , 309 ) , acute myelogenous leukemia ( 9 , 63 , 309 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 309 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 41 ) , acute myeloblastic leukemia, without maturation (M1) ( 41 ) , chronic lymphocytic leukemia ( 145 ) , chronic myelogenous leukemia ( 211 , 212 , 232 , 303 ) , T cell leukemia ( 4 , 68 , 105 ) , liver cancer ( 148 , 150 , 151 , 154 , 156 , 157 , 159 , 160 , 169 , 170 , 174 , 234 , 235 , 236 ) , hepatocellular carcinoma, surrounding tissue ( 219 ) , liver cancer, surrounding tissue ( 147 , 149 , 152 , 153 , 158 , 163 , 164 , 165 , 167 , 168 , 171 , 172 , 173 , 237 , 238 , 239 ) , lung cancer ( 15 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 46 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 127 , 139 , 140 , 146 , 186 , 187 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 216 , 222 , 224 , 226 , 228 , 230 , 243 , 244 , 245 , 246 , 247 , 248 , 252 , 254 , 255 , 256 , 262 , 266 , 298 ) , non-small cell lung cancer ( 26 , 27 , 28 , 30 , 31 , 32 , 35 , 36 , 37 , 43 , 45 , 46 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 139 , 140 , 146 , 186 , 187 , 191 , 192 , 194 , 195 , 196 , 197 , 198 , 200 , 201 , 202 , 203 , 204 , 205 , 216 , 222 , 224 , 226 , 228 , 230 , 243 , 244 , 246 , 247 , 248 , 252 , 254 , 262 , 266 , 298 ) , non-small cell lung cancer, surrounding tissue ( 221 , 223 , 231 , 253 ) , non-small cell lung adenocarcinoma ( 15 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 35 , 108 , 109 , 110 , 115 , 116 , 117 , 139 , 146 , 216 , 262 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 251 ) , non-small cell large cell lung carcinoma ( 27 , 30 , 111 , 118 ) , non-small cell squamous cell lung carcinoma ( 29 , 113 , 119 , 120 , 139 , 216 , 262 , 298 ) , small-cell lung cancer ( 24 , 25 ) , lung cancer, surrounding tissue ( 249 ) , lymphoma ( 20 , 68 , 309 ) , B cell lymphoma ( 41 , 68 ) , Burkitt's lymphoma ( 20 ) , non-Hodgkin's lymphoma ( 41 , 68 ) , follicular lymphoma ( 20 ) , mantle cell lymphoma ( 20 , 68 ) , neuroblastoma ( 40 , 297 ) , ovarian cancer ( 18 , 106 ) , pancreatic cancer ( 16 , 315 ) , pancreatic carcinoma ( 16 , 315 ) , pancreatic ductal adenocarcinoma ( 23 ) , multiple myeloma ( 1 , 41 , 190 ) , prostate cancer ( 8 , 106 , 240 , 242 , 288 , 310 ) , melanoma skin cancer ( 8 , 14 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 ) , fibrosarcoma of soft tissue ( 321 ) , leiomyosarcoma ( 125 ) , teratoma ( 189 ) , teratoma, surrounding tissue ( 162 ) , thyroid cancer ( 161 ) , thyroid cancer, surrounding tissue ( 166 ) , FTLD ( 126 )
Relevant cell line - cell type - tissue:
'brain, cerebral cortex' ( 126 ) , 'muscle, skeletal' ( 69 ) , 'pancreatic, ductal'-pancreas ( 23 ) , 'stem, embryonic' ( 286 ) , 1-LN (prostate cell) ( 8 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 304 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 143 ) , 293 (epithelial) ( 4 , 92 , 289 , 314 , 319 , 321 , 322 ) , 293E (epithelial) ( 95 ) , 786-O (renal) [VHL (human), transfection] ( 11 ) , 786-O (renal) ( 11 ) , 8227 (lymphoblast) ( 9 ) , A2780 (ovarian) ( 106 ) , A375 (melanocyte) ( 8 ) , A498 (renal) ( 175 ) , A549 (pulmonary) ( 26 , 33 , 43 , 298 ) , AN3-CA (endometrial) ( 125 ) , AU565 (breast cell) ( 39 ) , B lymphocyte-blood ( 190 ) , BJAB (B lymphocyte) ( 20 ) , breast ( 6 , 18 ) , BT-20 (breast cell) ( 46 ) , BT-474 (breast cell) ( 10 , 106 ) , BT-549 (breast cell) ( 46 ) , C33-A (cervical) ( 106 ) , C4-2 (prostate cell) ( 242 ) , Cal-12T (pulmonary) ( 32 ) , Calu 6 (pulmonary) ( 46 ) , Calu-3 (pulmonary) ( 28 , 108 ) , CFPAC-1 (pancreatic) ( 16 ) , CL1-0 (pulmonary) ( 127 ) , CL1-1 (pulmonary) ( 127 ) , CL1-2 (pulmonary) ( 127 ) , CL1-5 (pulmonary) ( 127 ) , COS (fibroblast) ( 321 ) , CTS (myeloid) ( 41 ) , DG75 (B lymphocyte) ( 128 ) , DMS153 (pulmonary) ( 31 ) , DMS53 (pulmonary) ( 25 ) , DMS79 (pulmonary) ( 24 ) , DOHH2 ('B lymphocyte, precursor') ( 41 ) , DU 145 (prostate cell) ( 8 ) , FL-18 (B lymphocyte) ( 20 ) , FL-318 (B lymphocyte) ( 20 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 48 ) , Flp-In T-Rex-293 (epithelial) ( 48 ) , germ cell-teratoma ( 162 ) , H2009 (pulmonary) ( 46 ) , H2077 (pulmonary) ( 46 ) , H2887 (pulmonary) ( 46 ) , H322M (pulmonary) ( 46 ) , HaCaT (keratinocyte) ( 206 ) , HCC1359 (pulmonary) ( 46 ) , HCC15 (pulmonary) ( 29 ) , HCC1937 (breast cell) ( 46 ) , HCC2279 (pulmonary) ( 46 ) , HCC366 (pulmonary) ( 46 ) , HCC4006 (pulmonary) ( 46 ) , HCC44 (pulmonary) ( 32 ) , HCC78 (pulmonary) ( 30 , 46 ) , HCC827 (pulmonary) ( 28 , 46 ) , HCT116 (intestinal) ( 106 , 287 , 298 , 316 ) , HEC-50B (endometrial) ( 125 ) , HEK293T (epithelial) ( 13 , 124 ) , HeLa (cervical) ( 5 , 17 , 38 , 91 , 122 , 217 , 218 , 250 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 291 , 300 , 304 , 318 ) , HeLa S3 (cervical) ( 241 , 299 ) , HeLa_Meta (cervical) ( 155 ) , HeLa_Pro (cervical) ( 155 ) , HeLa_Telo (cervical) ( 155 ) , hepatocyte-liver ( 219 , 320 ) , HepG2 (hepatic) ( 282 , 284 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 19 ) , HMLER ('stem, breast cancer') ( 19 ) , HOP62 (pulmonary) ( 46 ) , HT1080 (fibroblast) ( 319 , 321 ) , HUES-1 ('stem, embryonic') ( 2 ) , HUES-7 ('stem, embryonic') ( 2 , 285 ) , HUES-9 ('stem, embryonic') ( 2 , 121 ) , HUVEC (endothelial) ( 12 ) , Ishikawa (endometrial) ( 125 ) , JEG-3 (uterine) ( 123 ) , JEKO-1 (B lymphocyte) ( 20 , 68 ) , Jurkat (T lymphocyte) ( 4 , 34 , 51 , 52 , 55 , 56 , 57 , 58 , 59 , 68 , 70 , 93 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 207 , 208 , 257 , 258 , 259 , 265 , 293 , 294 , 295 , 296 , 301 , 305 , 312 ) , K562 (erythroid) ( 38 , 211 , 212 , 232 , 302 , 303 ) , KATO III (gastric) ( 260 , 264 ) , KG-1 (myeloid) ( 63 , 309 ) , KLE (endometrial) ( 125 ) , KPL-1 (breast cell) ( 106 ) , KPL-4 (breast cell) ( 39 ) , L6 (myoblast) ( 311 ) , LAN-1 (neural crest) ( 297 ) , LCLC-103H (pulmonary) ( 46 ) , liver ( 22 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 156 , 157 , 158 , 159 , 160 , 163 , 164 , 165 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 234 , 235 , 236 , 237 , 238 , 239 ) , LNCaP (prostate cell) ( 240 , 288 ) , LOU-NH91 (squamous) ( 29 , 46 , 119 ) , LS-513 (intestinal) ( 106 ) , lung ( 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 186 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 221 , 222 , 223 , 224 , 226 , 228 , 230 , 231 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 251 , 252 , 253 , 254 , 255 , 256 ) , MCF-7 (breast cell) [CYP19A1 (human)] ( 313 ) , MCF-7 (breast cell) ( 3 , 10 , 39 , 46 , 106 , 220 , 309 , 314 ) , MDA-IBC-3 (breast cell) ( 39 ) , MDA-MB-231 (breast cell) ( 39 , 46 , 106 ) , MDA-MB-435S (breast cell) ( 287 ) , MDA-MB-468 (breast cell) ( 39 , 46 ) , MEF (fibroblast) [PTEN (mouse)] ( 314 ) , MKN-45 (gastric) ( 44 , 64 , 65 , 66 , 67 , 107 , 129 , 138 , 142 , 209 , 210 , 213 , 214 , 215 , 225 , 227 , 229 , 261 , 263 ) , MV4-11 (macrophage) ( 41 , 287 ) , NB-4 (myeloid) ( 309 ) , NB10 (neural crest) ( 40 ) , NCCIT (epithelial) ( 189 ) , NCEB-1 (B lymphocyte) ( 20 ) , NCI-H128 (pulmonary) ( 24 ) , NCI-H1299 (pulmonary) ( 27 , 298 ) , NCI-H1355 (pulmonary) ( 26 ) , NCI-H1395 (pulmonary) ( 46 ) , NCI-H1417 (pulmonary) ( 24 ) , NCI-H1437 (pulmonary) ( 31 , 32 , 112 ) , NCI-H1568 (pulmonary) ( 46 ) , NCI-H157 (pulmonary) ( 46 ) , NCI-H1648 (pulmonary) ( 46 ) , NCI-H1650 (pulmonary) ( 28 , 117 , 187 , 298 ) , NCI-H1651 (pulmonary) ( 114 ) , NCI-H1666 (pulmonary) ( 32 , 46 ) , NCI-H1703 (squamous) ( 29 , 139 , 216 , 262 , 298 ) , NCI-H1734 (pulmonary) ( 27 ) , NCI-H1781 (pulmonary) ( 30 ) , NCI-H1792 (pulmonary) ( 26 ) , NCI-H1944 (pulmonary) ( 27 , 109 ) , NCI-H1975 (pulmonary) ( 28 ) , NCI-H2030 (pulmonary) ( 46 ) , NCI-H2073 (pulmonary) ( 29 , 31 ) , NCI-H209 (pulmonary) ( 24 , 31 ) , NCI-H2106 (pulmonary) ( 28 ) , NCI-H2170 (squamous) ( 113 ) , NCI-H2172 (pulmonary) ( 46 ) , NCI-H2228 (pulmonary) ( 30 , 35 , 281 , 283 ) , NCI-H23 (pulmonary) ( 26 , 298 ) , NCI-H2342 (pulmonary) ( 29 , 115 ) , NCI-H2405 (pulmonary) ( 32 ) , NCI-H3122 (pulmonary) ( 30 , 36 , 37 , 110 ) , NCI-H322 (pulmonary) ( 46 ) , NCI-H3255 (pulmonary) ( 45 , 47 , 140 , 279 , 280 ) , NCI-H345 (pulmonary) ( 317 ) , NCI-H358 (pulmonary) ( 27 ) , NCI-H441 (pulmonary) ( 26 , 116 , 146 ) , NCI-H446 (pulmonary) ( 25 ) , NCI-H460 (pulmonary) ( 27 , 46 , 111 , 266 , 290 , 298 ) , NCI-H510 (pulmonary) ( 317 ) , NCI-H520 (squamous) ( 46 , 120 ) , NCI-H524 (pulmonary) ( 24 ) , NCI-H526 (pulmonary) ( 25 ) , NCI-H647 (pulmonary) ( 46 ) , NCI-H661 (pulmonary) ( 30 , 118 ) , NCI-H69 (pulmonary) ( 25 , 317 ) , NCI-H82 (pulmonary) ( 25 ) , NCI-H838 (pulmonary) ( 31 ) , NPC (neural crest) ( 40 ) , NT2 (testicular) ( 188 ) , OCI-ly1 (B lymphocyte) ( 20 ) , OPM-2 (plasma cell) ( 41 ) , ovary ( 18 ) , P31/FUJ (erythroid) ( 41 ) , pancreas ( 315 ) , PC3 (prostate cell) ( 106 , 242 , 310 ) , PC9 (pulmonary) ( 15 , 46 ) , pituitary gland ( 308 ) , platelet-blood ( 306 ) , Raji (B lymphocyte) ( 20 ) , RAMOS (B lymphocyte) ( 20 ) , REC-1 (B lymphocyte) ( 20 ) , RL ('B lymphocyte, precursor') ( 41 ) , RPMI-8266 (plasma cell) ( 1 , 41 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 21 ) , SKBr3 (breast cell) ( 39 , 42 ) , skin ( 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 ) , SKUT-1 ( 125 ) , stomach ( 94 ) , SU-DHL-4 (B lymphocyte) ( 20 ) , SU-DHL-6 (B lymphocyte) ( 41 ) , SUM149 (breast cell) ( 39 ) , SUM159 (breast cell) ( 39 ) , SUM190 (breast cell) ( 39 ) , SW1463 (intestinal) ( 106 ) , T47D (breast cell) ( 3 , 106 ) , TF-1 (erythroid) ( 309 ) , thyroid ( 161 , 166 ) , U-937 (myeloid) ( 309 ) , U266 (plasma cell) ( 41 ) , U2OS (bone cell) ( 233 ) , U373 MG (glial) ( 8 ) , UPN-1 (B lymphocyte) ( 20 ) , WM115 (melanocyte) ( 292 ) , WM239A (melanocyte) ( 14 )

Upstream Regulation
Regulatory protein:
AMIGO2 (human) ( 12 ) , DYRK2 (human) ( 3 ) , GRP78 (human) ( 123 ) , HRas (human) ( 316 ) , KRas (human) ( 316 ) , LKB1 (human) ( 298 ) , PDK1 (human) ( 316 ) , SHP-1 (human) ( 92 )
Putative in vivo kinases:
PDK1 (human) ( 16 , 322 ) , PKCT (human) ( 4 )
Kinases, in vitro:
PDK1 (human) ( 16 , 307 , 321 , 322 )
Treatments:
2-deoxyglucose ( 266 ) , alpha2-macroglobulin ( 8 ) , BX795 ( 8 ) , calyculin_A ( 306 ) , ceramide ( 16 ) , estrogen_deprivation ( 313 ) , FTI277 ( 316 ) , ghrelin ( 92 ) , GSK2334470 ( 1 ) , IGF-1 ( 220 , 314 ) , insulin ( 311 ) , ionizing_radiation ( 316 ) , IP(6) ( 242 ) , IQA ( 312 ) , ischemia ( 18 ) , KP-372-1 ( 309 ) , lapatinib ( 42 ) , LY294002 ( 312 ) , methyl-beta-cyclodextrin ( 206 ) , miRNA ( 9 ) , naltrindole ( 317 ) , OSI-027 ( 68 ) , PDK1_inhibitor_1 ( 124 ) , PDK1_inhibitor_2 ( 124 ) , PDK1_inhibitor_3 ( 124 ) , QLT0254 ( 315 ) , rapamycin ( 68 ) , sardomozide ( 297 ) , selenite ( 310 ) , siRNA ( 298 , 316 ) , TBB ( 312 ) , thrombin ( 306 ) , tunicamycin ( 123 ) , VEGF ( 12 )

Downstream Regulation
Effects of modification on PDK1:
enzymatic activity, induced ( 16 , 105 , 307 , 320 , 321 , 322 ) , molecular association, regulation ( 321 ) , phosphorylation ( 16 )
Effects of modification on biological processes:
carcinogenesis, induced ( 106 ) , cell growth, induced ( 8 )
Induce interaction with:
14-3-3 eta (human) ( 321 ) , 14-3-3 theta (human) ( 321 )

References 

1

Yang C, et al. (2017) PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget 8, 39185-39197
28402933   Curated Info

2

Wang XQ, et al. (2017) CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death Differ 24, 38-48
27636107   Curated Info

3

Mimoto R, et al. (2017) Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. Cancer Lett 384, 27-38
27746162   Curated Info

4

Kang JA, et al. (2017) PKCθ-Mediated PDK1 Phosphorylation Enhances T Cell Activation by Increasing PDK1 Stability. Mol Cells 40, 37-44
28152304   Curated Info

5

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

8

Gopal U, Gonzalez-Gronow M, Pizzo SV (2016) Activated α2-Macroglobulin Regulates Transcriptional Activation of c-MYC Target Genes through Cell Surface GRP78 Protein. J Biol Chem 291, 10904-15
27002159   Curated Info

9

Lechman ER, et al. (2016) miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell 29, 214-28
26832662   Curated Info

10

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

11

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

12

Park H, et al. (2015) AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation. J Cell Biol 211, 619-37
26553931   Curated Info

13

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

14

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

15

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

16

Caohuy H, et al. (2014) Activation of 3-Phosphoinositide-dependent Kinase 1 (PDK1) and Serum- and Glucocorticoid-induced Protein Kinase 1 (SGK1) by Short-chain Sphingolipid C4-ceramide Rescues the Trafficking Defect of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (ΔF508-CFTR). J Biol Chem 289, 35953-68
25384981   Curated Info

17

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

18

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

19

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

20

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

21

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

22

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

23

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

24

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

25

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

26

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

27

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

28

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

29

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

30

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

31

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

32

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

33

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

34

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

35

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

36

Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

37

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

38

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

39

Robertson FM, et al. (2013) Presence of anaplastic lymphoma kinase in inflammatory breast cancer. Springerplus 2, 497
24102046   Curated Info

40

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

41

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

42

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

43

Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info

44

Rikova K (2012) CST Curation Set: 16141; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

45

Rikova K (2012) CST Curation Set: 16142; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

46

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

47

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

48

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

49

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

50

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

51

Guo A (2012) CST Curation Set: 13981; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

52

Guo A (2012) CST Curation Set: 13982; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

53

Rikova K (2012) CST Curation Set: 13915; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -;
Curated Info

54

Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -;
Curated Info

55

Guo A (2012) CST Curation Set: 13866; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

56

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

57

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

59

Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Rikova K (2012) CST Curation Set: 13733; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

61

Rikova K (2012) CST Curation Set: 13732; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

62

Rikova K (2012) CST Curation Set: 13734; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

63

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

64

Mulhern D (2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

65

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

66

Mulhern D (2012) CST Curation Set: 13458; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

67

Mulhern D (2012) CST Curation Set: 13459; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

68

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

69

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

70

Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

71

Rikova K (2011) CST Curation Set: 13113; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

72

Rikova K (2011) CST Curation Set: 13114; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

73

Rikova K (2011) CST Curation Set: 13115; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

74

Rikova K (2011) CST Curation Set: 13116; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

75

Rikova K (2011) CST Curation Set: 13117; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

76

Rikova K (2011) CST Curation Set: 13118; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Rikova K (2011) CST Curation Set: 13119; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

78

Rikova K (2011) CST Curation Set: 13120; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

79

Rikova K (2011) CST Curation Set: 13121; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

80

Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

81

Rikova K (2011) CST Curation Set: 13123; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

82

Rikova K (2011) CST Curation Set: 13124; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

83

Rikova K (2011) CST Curation Set: 13125; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

84

Rikova K (2011) CST Curation Set: 13126; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

85

Rikova K (2011) CST Curation Set: 13127; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

86

Rikova K (2011) CST Curation Set: 13128; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

87

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

88

Rikova K (2011) CST Curation Set: 13130; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

89

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

90

Rikova K (2011) CST Curation Set: 13132; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

91

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

92

Lodeiro M, et al. (2011) The SHP-1 protein tyrosine phosphatase negatively modulates Akt signaling in the ghrelin/GHSR1a system. Mol Biol Cell 22, 4182-91
21900501   Curated Info

93

Mulhern D (2011) CST Curation Set: 12713; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

94

Rikova K (2011) CST Curation Set: 12176; Year: 2011; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

96

Guo A (2011) CST Curation Set: 11885; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

97

Guo A (2011) CST Curation Set: 11886; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

98

Guo A (2011) CST Curation Set: 11887; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

99

Guo A (2011) CST Curation Set: 11888; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

100

Guo A (2011) CST Curation Set: 11889; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

101

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

102

Guo A (2011) CST Curation Set: 11891; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

103

Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

104

Guo A (2011) CST Curation Set: 11893; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

105

Thayyullathil F, et al. (2011) Protein phosphatase 1-dependent dephosphorylation of Akt is the prime signaling event in sphingosine-induced apoptosis in Jurkat cells. J Cell Biochem 112, 1138-53
21308747   Curated Info

106

Nagashima K, et al. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 286, 6433-48
21118801   Curated Info

107

Guo A (2011) CST Curation Set: 11300; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

108

Rikova K (2011) CST Curation Set: 10887; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

109

Rikova K (2011) CST Curation Set: 10919; Year: 2011; Biosample/Treatment: cell line, NCI-H1944/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

110

Rikova K (2011) CST Curation Set: 10921; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

111

Rikova K (2011) CST Curation Set: 10893; Year: 2011; Biosample/Treatment: cell line, NCI-H460/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

112

Rikova K (2011) CST Curation Set: 10899; Year: 2011; Biosample/Treatment: cell line, NCI-H1437/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

113

Rikova K (2011) CST Curation Set: 10915; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

114

Rikova K (2011) CST Curation Set: 10917; Year: 2011; Biosample/Treatment: cell line, NCI-H1651/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

115

Rikova K (2011) CST Curation Set: 10885; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

116

Rikova K (2011) CST Curation Set: 10913; Year: 2011; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

117

Rikova K (2011) CST Curation Set: 10909; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

118

Rikova K (2011) CST Curation Set: 10897; Year: 2011; Biosample/Treatment: cell line, NCI-H661/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

119

Rikova K (2011) CST Curation Set: 10891; Year: 2011; Biosample/Treatment: cell line, LOU-NH91/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

120

Rikova K (2011) CST Curation Set: 10911; Year: 2011; Biosample/Treatment: cell line, NCI-H520/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

121

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

122

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

123

Yung HW, Charnock-Jones DS, Burton GJ (2011) Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 6, e17894
21445305   Curated Info

124

Paweletz CP, et al. (2011) Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One 6, e26459
22039492   Curated Info

125

Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6, e26343
22039466   Curated Info

126

Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79
20886841   Curated Info

127

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

128

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

129

Moritz A (2010) CST Curation Set: 10605; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

130

Possemato A (2010) CST Curation Set: 10145; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

131

Possemato A (2010) CST Curation Set: 10158; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

132

Possemato A (2010) CST Curation Set: 10162; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

133

Possemato A (2010) CST Curation Set: 10159; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

134

Possemato A (2010) CST Curation Set: 10152; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

135

Possemato A (2010) CST Curation Set: 10147; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

136

Possemato A (2010) CST Curation Set: 10163; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

137

Possemato A (2010) CST Curation Set: 10153; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

138

Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

139

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

140

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

141

Rikova K (2010) CST Curation Set: 10041; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

142

Rikova K (2010) CST Curation Set: 10046; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

143

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

144

Rikova K (2010) CST Curation Set: 10037; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 serum free/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

145

Rikova K (2010) CST Curation Set: 10035; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11/untreated; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

146

Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

147

Tucker M (2010) CST Curation Set: 9865; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

148

Tucker M (2010) CST Curation Set: 9864; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

149

Tucker M (2010) CST Curation Set: 9867; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

150

Tucker M (2010) CST Curation Set: 9866; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

151

Tucker M (2010) CST Curation Set: 9870; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

152

Tucker M (2010) CST Curation Set: 9863; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

153

Tucker M (2010) CST Curation Set: 9869; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

154

Tucker M (2010) CST Curation Set: 9868; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

155

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

156

Tucker M (2010) CST Curation Set: 9850; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

157

Tucker M (2010) CST Curation Set: 9834; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

158

Tucker M (2010) CST Curation Set: 9835; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

159

Tucker M (2010) CST Curation Set: 9842; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

160

Tucker M (2010) CST Curation Set: 9832; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

161

Tucker M (2010) CST Curation Set: 9848; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

162

Tucker M (2010) CST Curation Set: 9847; Year: 2010; Biosample/Treatment: cell line, xy3-145N/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

163

Tucker M (2010) CST Curation Set: 9851; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

164

Tucker M (2010) CST Curation Set: 9843; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

165

Tucker M (2010) CST Curation Set: 9853; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

166

Tucker M (2010) CST Curation Set: 9849; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

167

Tucker M (2010) CST Curation Set: 9855; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

168

Tucker M (2010) CST Curation Set: 9833; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

169

Tucker M (2010) CST Curation Set: 9836; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

170

Tucker M (2010) CST Curation Set: 9830; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

171

Tucker M (2010) CST Curation Set: 9825; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

172

Tucker M (2010) CST Curation Set: 9841; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

173

Tucker M (2010) CST Curation Set: 9837; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

174

Tucker M (2010) CST Curation Set: 9844; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

175

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

176

Guo A (2010) CST Curation Set: 9886; Year: 2010; Biosample/Treatment: cell line, no cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

177

Tucker M (2010) CST Curation Set: 9779; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

178

Tucker M (2010) CST Curation Set: 9778; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

179

Tucker M (2010) CST Curation Set: 9777; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

180

Tucker M (2010) CST Curation Set: 9783; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

181

Tucker M (2010) CST Curation Set: 9782; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

182

Tucker M (2010) CST Curation Set: 9784; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

183

Tucker M (2010) CST Curation Set: 9786; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

184

Tucker M (2010) CST Curation Set: 9781; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

185

Tucker M (2010) CST Curation Set: 9785; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

186

Rikova K (2010) CST Curation Set: 9764; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

187

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

188

Zhou J (2010) CST Curation Set: 9673; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

189

Zhou J (2010) CST Curation Set: 9672; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

190

Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90
20230923   Curated Info

191

Rikova K (2010) CST Curation Set: 9470; Year: 2010; Biosample/Treatment: tissue, /untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

192

Rikova K (2010) CST Curation Set: 9452; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

193

Rikova K (2010) CST Curation Set: 9451; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

194

Rikova K (2010) CST Curation Set: 9461; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

195

Rikova K (2010) CST Curation Set: 9468; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

196

Rikova K (2010) CST Curation Set: 9453; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

197

Rikova K (2010) CST Curation Set: 9460; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

198

Rikova K (2010) CST Curation Set: 9456; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

199

Rikova K (2010) CST Curation Set: 9469; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

200

Rikova K (2010) CST Curation Set: 9457; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

201

Rikova K (2010) CST Curation Set: 9458; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

202

Rikova K (2010) CST Curation Set: 9471; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

203

Rikova K (2010) CST Curation Set: 9450; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

204

Rikova K (2010) CST Curation Set: 9449; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

205

Rikova K (2010) CST Curation Set: 9464; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

206

Calay D, et al. (2010) Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol 130, 1136-45
20054340   Curated Info

207

Possemato A (2010) CST Curation Set: 9394; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

208

Possemato A (2010) CST Curation Set: 9395; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

209

Rikova K (2010) CST Curation Set: 9329; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

210

Rikova K (2010) CST Curation Set: 9328; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

211

Rikova K (2010) CST Curation Set: 9327; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

212

Rikova K (2010) CST Curation Set: 9326; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

213

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

214

Moritz A (2010) CST Curation Set: 9280; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

215

Moritz A (2010) CST Curation Set: 9281; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

216

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

217

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

218

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

219

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

220

Alberobello AT, et al. (2010) Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem 285, 6563-72
20044479   Curated Info

221

Rikova K (2010) CST Curation Set: 9216; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

222

Rikova K (2010) CST Curation Set: 9219; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

223

Rikova K (2010) CST Curation Set: 9220; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

224

Rikova K (2010) CST Curation Set: 9214; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

225

Possemato A (2010) CST Curation Set: 9177; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

226

Rikova K (2010) CST Curation Set: 9211; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

227

Possemato A (2010) CST Curation Set: 9178; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

228

Rikova K (2010) CST Curation Set: 9215; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

229

Possemato A (2010) CST Curation Set: 9179; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

230

Rikova K (2010) CST Curation Set: 9213; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

231

Rikova K (2010) CST Curation Set: 9218; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

232

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

233

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

234

Tucker M (2010) CST Curation Set: 8912; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

235

Tucker M (2010) CST Curation Set: 8908; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

236

Tucker M (2010) CST Curation Set: 8914; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

237

Tucker M (2010) CST Curation Set: 8911; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

238

Tucker M (2010) CST Curation Set: 8909; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

239

Tucker M (2010) CST Curation Set: 8915; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

240

Chen L, Giorgianni F, Beranova-Giorgianni S (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9, 174-8
20044836   Curated Info

241

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

242

Gu M, et al. (2009) Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res 69, 9465-72
19920184   Curated Info

243

Rikova K (2009) CST Curation Set: 8566; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

244

Rikova K (2009) CST Curation Set: 8541; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

245

Rikova K (2009) CST Curation Set: 8549; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

246

Rikova K (2009) CST Curation Set: 8551; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

247

Rikova K (2009) CST Curation Set: 8553; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

248

Rikova K (2009) CST Curation Set: 8545; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

249

Rikova K (2009) CST Curation Set: 8547; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

250

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

251

Rikova K (2009) CST Curation Set: 8535; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

252

Rikova K (2009) CST Curation Set: 8537; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

253

Rikova K (2009) CST Curation Set: 8539; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

254

Rikova K (2009) CST Curation Set: 8513; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

255

Rikova K (2009) CST Curation Set: 8529; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

256

Rikova K (2009) CST Curation Set: 8509; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

257

Possemato A (2009) CST Curation Set: 8345; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

258

Possemato A (2009) CST Curation Set: 8346; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

259

Possemato A (2009) CST Curation Set: 8363; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

260

Possemato A (2009) CST Curation Set: 8414; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

261

Possemato A (2009) CST Curation Set: 8412; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

262

Possemato A (2009) CST Curation Set: 8410; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

263

Possemato A (2009) CST Curation Set: 8411; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

264

Possemato A (2009) CST Curation Set: 8413; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

265

Possemato A (2009) CST Curation Set: 8038; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

266

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

267

Zhou J (2009) CST Curation Set: 7600; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

268

Zhou J (2009) CST Curation Set: 7598; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

269

Zhou J (2009) CST Curation Set: 7597; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

270

Zhou J (2009) CST Curation Set: 7596; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

271

Zhou J (2009) CST Curation Set: 7595; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

272

Zhou J (2009) CST Curation Set: 7599; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

273

Zhou J (2009) CST Curation Set: 7590; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

274

Zhou J (2009) CST Curation Set: 7593; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

275

Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

276

Zhou J (2009) CST Curation Set: 7594; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

277

Zhou J (2009) CST Curation Set: 7591; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

278

Zhou J (2009) CST Curation Set: 7589; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

279

Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

280

Possemato A (2009) CST Curation Set: 7416; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

281

Possemato A (2009) CST Curation Set: 7410; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

282

Possemato A (2009) CST Curation Set: 7408; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

283

Possemato A (2009) CST Curation Set: 7409; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

284

Possemato A (2009) CST Curation Set: 7407; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

285

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

286

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

287

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

288

Zhou J (2009) CST Curation Set: 7215; Year: 2009; Biosample/Treatment: cell line, LNCaP/untreated; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

289

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

290

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

291

Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20
19351860   Curated Info

292

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

293

Zhou J (2009) CST Curation Set: 6542; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

294

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

295

Possemato A (2008) CST Curation Set: 5708; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

296

Possemato A (2008) CST Curation Set: 5709; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

297

Koomoa DL, et al. (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68, 9825-31
19047162   Curated Info

298

Zhong D, et al. (2008) LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 68, 7270-7
18794113   Curated Info

299

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

300

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

301

Possemato A (2008) CST Curation Set: 4821; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

302

Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

303

Stokes M (2008) CST Curation Set: 4389; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

304

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

305

Stokes M (2008) CST Curation Set: 3883; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

306

Lerea KM, Venjara AY, Olson SC, Kelly MR (2007) Threonine phosphorylation of integrin beta3 in calyculin A-treated platelets is selectively sensitive to 5'-iodotubercidin. Biochim Biophys Acta 1773, 185-91
17052767   Curated Info

307

Gao X, Harris TK (2006) Role of the PH domain in regulating in vitro autophosphorylation events required for reconstitution of PDK1 catalytic activity. Bioorg Chem 34, 200-23
16780920   Curated Info

308

Beranova-Giorgianni S, Zhao Y, Desiderio DM, Giorgianni F (2006) Phosphoproteomic analysis of the human pituitary. Pituitary 9, 109-20
16807684   Curated Info

309

Zeng Z, et al. (2006) Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66, 3737-46
16585200   Curated Info

310

Wu Y, et al. (2006) Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 5, 246-52
16505097   Curated Info

311

Fiory F, et al. (2005) Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by the insulin receptor is necessary for insulin metabolic signaling. Mol Cell Biol 25, 10803-14
16314505   Curated Info

312

Di Maira G, et al. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12, 668-77
15818404   Curated Info

313

Sabnis GJ, Jelovac D, Long B, Brodie A (2005) The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65, 3903-10
15867390   Curated Info

314

Scheid MP, Parsons M, Woodgett JR (2005) Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol Cell Biol 25, 2347-63
15743829   Curated Info

315

Yau CY, Wheeler JJ, Sutton KL, Hedley DW (2005) Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 65, 1497-504
15735038   Curated Info

316

Carón RW, et al. (2005) Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 4, 257-70
15713897   Curated Info

317

Chen YL, Law PY, Loh HH (2004) Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res 64, 8723-30
15574783   Curated Info

318

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info

319

Sato S, Fujita N, Tsuruo T (2004) Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 279, 33759-67
15175348   Curated Info

320

Lim MA, Kikani CK, Wick MJ, Dong LQ (2003) Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function. Proc Natl Acad Sci U S A 100, 14006-11
14623982   Curated Info

321

Sato S, Fujita N, Tsuruo T (2002) Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3. J Biol Chem 277, 39360-7
12177059   Curated Info

322

Casamayor A, Morrice NA, Alessi DR (1999) Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342 ( Pt 2), 287-92
10455013   Curated Info